Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity

about

Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity

Item

http://www.wikidata.org/entity/Q42142601

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Design considerations and anal ...... e of possible non-monotonicity

@en

Design considerations and anal ...... e of possible non-monotonicity

@nl

type

Item

label

Design considerations and anal ...... e of possible non-monotonicity

@en

Design considerations and anal ...... e of possible non-monotonicity

@nl

prefLabel

Design considerations and anal ...... e of possible non-monotonicity

@en

Design considerations and anal ...... e of possible non-monotonicity

@nl

P1476

Design considerations and anal ...... e of possible non-monotonicity

@en

P2093

Stephen J Walters

http://www.w3.org/2001/XMLSchema#string

Steven A Julious

http://www.w3.org/2001/XMLSchema#string

P2860

Dual effects of phytoestrogens result in u-shaped dose-response curves

Fitting Emax models to clinical trial dose-response data when the high dose asymptote is ill defined.

Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer

U-shaped dose-responses in biology, toxicology, and public health.

Clinical development success rates for investigational drugs.

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.

Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials.

Colloidal drug formulations can explain "bell-shaped" concentration-response curves.

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.

Bayesian hierarchical modelling for inferring genetic interactions in yeast.

P2888

s12874-017-0416-3

P304

149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12874-017-0416-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Feng Liu

P577

2017-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092052224

http://www.w3.org/2001/XMLSchema#string

P698

28969588

http://www.w3.org/2001/XMLSchema#string

P932

5625783

http://www.w3.org/2001/XMLSchema#string